Granulosa theca cell tumor represents a specific subset of ovarian sex cord-stromal tumors, originating from the theca cells that surround the developing follicle. These neoplasms are typically hormone-active, frequently secreting estrogen and leading to pronounced clinical manifestations long before the mass is identified. While relatively rare compared to epithelial ovarian malignancies, their predictable hormonal effects and generally favorable prognosis make them a critical diagnosis for gynecologists and pathologists to recognize promptly.
Pathogenesis and Cellular Characteristics
The theca layer of the ovarian follicle is responsible for producing androstenedione, which is then converted to estrogen by the granulosa cells within the developing follicle. A granulosa theca cell tumor arises when the thecal cells themselves undergo monoclonal transformation, gaining the ability to autonomously produce estrogen. This dysregulation is often linked to mutations in genes such as FOXL2, which plays a pivotal role in maintaining the identity of adult granulosa cells. The resulting tumor cells resemble their normal theca counterparts, forming solid sheets, trabeculae, or cords within a delicate fibrovascular stroma.
Clinical Presentation and Hormonal Impact
Because these tumors are frequently hormonally active, patients often present with symptoms related to estrogen excess rather than vague abdominal complaints. In premenopausal women, this can manifest as menstrual irregularity, intermenstrual bleeding, or menorrhagia. Postmenopausal patients are more likely to present with postmenopausal bleeding, a symptom that demands immediate and thorough evaluation. In rare instances, the tumor may produce significant amounts of testosterone, leading to signs of virilization such as deepening of the voice, hirsutism, or clitoromegaly.
Associated Clinical Features
Abnormal uterine bleeding, the most common presenting symptom.
Pelvic mass or pressure, often discovered incidentally.
Symptoms of estrogen excess, including endometrial hyperplasia.
Potential for pleural effusion or ascites in advanced cases (Meigs syndrome overlap).
Diagnostic Pathway and Imaging
The diagnostic journey begins with a high index of suspicion based on the clinical presentation. Transvaginal ultrasound is typically the first imaging modality, revealing a solid-appearing ovarian mass with variable vascularity on Doppler. Due to the hormonal activity, the endometrium is often thickened, which serves as a crucial ancillary finding. Tumor marker assessment, including CA-125, inhibin B, and anti-Müllerian hormone (AMH), is essential; inhibin levels are characteristically elevated and serve as a valuable tool for monitoring response to treatment or detecting recurrence.
Management and Surgical Approach
The primary treatment for a confirmed granulosa theca cell tumor is surgical intervention. For patients with early-stage disease who desire future fertility, a unilateral salpingo-oophorectomy may be considered, provided strict criteria are met and thorough counseling is performed. However, for the majority of patients, particularly those who are postmenopausal or have completed childbearing, a total abdominal hysterectomy with bilateral salpingo-oophorectomy is the standard of care. This approach ensures complete removal of the hormonally active tissue and allows for adequate staging to rule out occult spread.
